The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Hugo Arias-PulidoA Cimino-MathewsN ChaherC QuallsN JosteC ColpaertJ D MarottiM FoiseyE R ProssnitzL A EmensS FieringPublished in: Breast cancer research and treatment (2018)
CD20+TILs/PD-L1+TILs status represents an independent favorable prognostic factor in IBC and TN IBC, suggesting a critical role for B cells in antitumor immune responses. Anti-PD-1/PD-L1 and B cell-activating immunotherapies should be explored in these settings.